Ultragenyx Pharmaceutical Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	175	421	174	213.58	132.94	307.58
Short-Term Investments	238	259	436	363.63	614.82	432.61
Cash & Short-Term Investments	413	680	610	577.21	747.76	740.2
Cash Growth	-16.47%	11.47%	5.68%	-22.81%	1.02%	-38.40%
Accounts Receivable	121	158	122	73.39	40.45	28.43
Inventory	55	52	45	33.97	26.77	16.23
Other Current Assets	68	61	40	47.62	68.93	71.75
Total Current Assets	657	951	817	732.18	883.9	856.6
Net Property, Plant & Equipment	239	244	266	290.57	259.73	176.18
Other Intangible Assets	174	176	178	166.27	160.11	130.79
Goodwill	44	44	44	44.41	44.41	44.41
Long-Term Investments	121	57	135	199.9	148.97	293.86
Other Long-Term Assets	61	60	63	57.69	48.34	20.56
Total Assets	1,296	1,532	1,503	1,491	1,545	1,522
Accounts Payable	42	31	39	42.11	43.27	17.14
Accrued Expenses	194	265	241	196.49	204.68	145.56
Current Portion of Leases	-	12	10	12.6	11.78	11.07
Unearned Revenue	-	-	-	-	1.48	7.61
Other Current Liabilities	89	76	54	29.24	-	-
Total Current Liabilities	325	384	344	280.44	261.21	181.37
Long-Term Leases	-	24	30	30.57	19.81	30.9
Other Long-Term Liabilities	1,200	1,197	867	904.59	911.93	387.56
Total Long-Term Liabilities	1,200	1,221	897	935.16	931.74	418.47
Total Liabilities	1,525	1,605	1,241	1,216	1,193	599.84
Common Stock	-	8	4	0.08	0.07	0.07
Treasury Stock	-10	-8	-4	-0.43	-	-
Additional Paid-in Capital	4,481	4,451	4,213	3,662	3,140	2,998
Accumulated Other Comprehensive Income	10	1	-1	1.08	-6.57	-1.4
Retained Earnings	-4,717	-4,532	-3,957	-3,388	-2,781	-2,074
Total Common Shareholders' Equity	-236	-80	255	275.41	352.49	922.56
Minority Interest	7	7	7	-	-	-
Shareholders' Equity	-229	-73	262	275.41	352.49	922.56
Total Liabilities & Equity	1,296	1,532	1,503	1,491	1,545	1,522
Total Debt	-	36	40	43.17	31.59	41.97
Net Cash (Debt)	413	644	570	534.04	716.17	698.23
Net Cash Growth	-35.87%	12.98%	6.73%	-25.43%	2.57%	-39.46%
Net Cash Per Share	4.14	6.53	6.30	7.27	10.24	10.30
Book Value	-236	-80	255	275.41	352.49	922.56
Book Value Per Share	-2.37	-0.81	2.82	3.75	5.04	13.61
Tangible Book Value	-454	-300	33	64.74	147.98	747.37
Tangible Book Value Per Share	-4.55	-3.04	0.36	0.88	2.12	11.02

SEC Filings: 10-K · 10-Q